Research Analysts’ Recent Ratings Changes for Tempus AI (TEM)

Several analysts have recently updated their ratings and price targets for Tempus AI (NASDAQ: TEM):

• 9/9/2026 – Tempus AI is now covered by UBS Group AG. They set a “neutral” rating and a $70.00 price target on the stock.
• 9/8/2026 – Tempus AI is now covered by Rothschild & Co Redburn. They set a “neutral” rating and a $67.00 price target on the stock.
• 9/8/2026 – Tempus AI is now covered by Rothschild & Co Redburn. They set a “neutral” rating and a $67.00 price target on the stock.
• 9/8/2026 – Tempus AI is now covered by Roth Capital. They set a “neutral” rating and a $67.00 price target on the stock.
• 9/2/2026 – Tempus AI was given a new $80.00 price target by Raymond James Financial, Inc..
• 9/2/2026 – Tempus AI is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $80.00 price target on the stock.
• 9/1/2026 – Tempus AI was upgraded by Piper Sandler from “neutral” to “overweight”. They now have a $76.00 price target on the stock, up from $56.00.
• 8/27/2026 – Tempus AI was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 8/20/2026 – Tempus AI had its price target raised by BTIG Research from $70.00 to $80.00. They now have a “buy” rating on the stock.
• 8/12/2026 – Tempus AI was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/4/2026 – Tempus AI had its price target lowered by Piper Sandler from $58.00 to $56.00. They now have a “neutral” rating on the stock.
• 8/3/2026 – Tempus AI had its price target lowered by BTIG Research from $80.00 to $70.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Tempus AI had its price target lowered by HC Wainwright from $64.00 to $56.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Tempus AI had its price target lowered by Stifel Nicolaus from $60.00 to $50.00. They now have a “hold” rating on the stock.
• 7/31/2026 – Tempus AI had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $75.00 price target on the stock.
• 7/25/2026 – Tempus AI was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/24/2026 – Tempus AI had its “buy” rating reaffirmed by HC Wainwright.
• 7/20/2026 – Tempus AI was downgraded by Lake Street Capital to “hold”.
• 7/20/2026 – Tempus AI had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $75.00 price target on the stock.
• 7/16/2026 – Tempus AI had its price target raised by Guggenheim from $60.00 to $65.00. They now have a “buy” rating on the stock.
• 7/15/2026 – Tempus AI had its “buy” rating reaffirmed by TD Cowen.

Insider Buying and Selling at Tempus AI

In related news, Director Nadja West sold 3,000 shares of Tempus AI stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $69.00, for a total value of $207,000.00. Following the completion of the transaction, the director owned 31,981 shares in the company, valued at approximately $2,206,689. The trade was a 8.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James Rogers sold 26,313 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the sale, the chief financial officer directly owned 106,024 shares in the company, valued at approximately $6,361,440. The trade was a 19.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 1,043,988 shares of company stock valued at $56,963,417. Corporate insiders own 24.26% of the company’s stock.

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.